Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$19.78
-2.8%
$18.92
$14.40
$47.00
$1.31B1.39900,642 shs1.67 million shs
Innoviva, Inc. stock logo
INVA
Innoviva
$19.15
+0.9%
$18.19
$15.20
$21.28
$1.20B0.35639,282 shs1.04 million shs
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
$3.36
$0.00
$2.47
$5.98
$344.00M2.351.69 million shs2.60 million shs
MannKind Co. stock logo
MNKD
MannKind
$4.20
+1.9%
$4.70
$4.05
$7.63
$1.25B1.142.38 million shs1.81 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-2.80%-3.47%+1.07%-4.12%-46.42%
Innoviva, Inc. stock logo
INVA
Innoviva
+0.95%+1.97%+4.99%+6.98%+21.36%
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
MannKind Co. stock logo
MNKD
MannKind
+1.94%-3.67%-11.39%-23.22%-12.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
1.8949 of 5 stars
4.50.00.00.03.60.00.0
Innoviva, Inc. stock logo
INVA
Innoviva
4.3419 of 5 stars
3.51.00.04.23.02.51.9
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
MannKind Co. stock logo
MNKD
MannKind
2.7934 of 5 stars
3.61.00.00.02.81.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.90
Moderate Buy$53.90172.50% Upside
Innoviva, Inc. stock logo
INVA
Innoviva
3.00
Buy$55.00187.21% Upside
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
0.00
N/AN/AN/A
MannKind Co. stock logo
MNKD
MannKind
3.25
Buy$10.00138.10% Upside

Current Analyst Ratings Breakdown

Latest KERX, CLDX, MNKD, and INVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$44.00 ➝ $38.00
5/9/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.00
5/9/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.00
5/6/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
4/28/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$64.00
4/10/2025
MannKind Co. stock logo
MNKD
MannKind
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$12.00
4/9/2025
MannKind Co. stock logo
MNKD
MannKind
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/20/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$46.00
3/7/2025
Innoviva, Inc. stock logo
INVA
Innoviva
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$55.00
3/3/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$42.00 ➝ $36.00
2/28/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$7.56M173.71N/AN/A$9.08 per share2.18
Innoviva, Inc. stock logo
INVA
Innoviva
$369.84M3.25$3.70 per share5.17$10.66 per share1.80
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
$60.64M5.67N/AN/A($0.12) per share-28.00
MannKind Co. stock logo
MNKD
MannKind
$297.60M4.29N/AN/A($0.91) per share-4.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$141.43M-$2.70N/AN/AN/A-1,544.32%-19.75%-18.86%8/14/2025 (Estimated)
Innoviva, Inc. stock logo
INVA
Innoviva
$179.72M-$1.0127.7512.35N/A18.31%20.84%11.38%7/29/2025 (Estimated)
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
-$163.44M-$0.88N/AN/AN/A-96.41%N/A-60.05%N/A
MannKind Co. stock logo
MNKD
MannKind
-$11.94M$0.1060.0018.26N/A8.07%-17.74%8.68%8/6/2025 (Estimated)

Latest KERX, CLDX, MNKD, and INVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million
5/8/2025Q1 2025
MannKind Co. stock logo
MNKD
MannKind
$0.03$0.04+$0.01$0.04$75.86 million$78.35 million
5/7/2025Q1 2025
Innoviva, Inc. stock logo
INVA
Innoviva
N/A$0.25N/A-$0.74N/A$88.63 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
N/AN/AN/AN/AN/A
MannKind Co. stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
24.27
24.27
Innoviva, Inc. stock logo
INVA
Innoviva
0.38
1.79
1.64
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
N/A
2.21
1.19
MannKind Co. stock logo
MNKD
MannKind
N/A
4.54
4.17

Institutional Ownership

CompanyInstitutional Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
69.00%
MannKind Co. stock logo
MNKD
MannKind
49.55%

Insider Ownership

CompanyInsider Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
3.80%
Innoviva, Inc. stock logo
INVA
Innoviva
2.25%
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
1.61%
MannKind Co. stock logo
MNKD
MannKind
3.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
15066.38 million63.82 millionOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
10062.78 million61.54 millionOptionable
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
N/A102.38 millionN/AOptionable
MannKind Co. stock logo
MNKD
MannKind
400303.93 million267.51 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$19.78 -0.57 (-2.80%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$20.35 +0.57 (+2.88%)
As of 05/27/2025 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Innoviva stock logo

Innoviva NASDAQ:INVA

$19.15 +0.18 (+0.95%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$19.10 -0.05 (-0.26%)
As of 05/27/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Keryx Biopharmaceuticals stock logo

Keryx Biopharmaceuticals NASDAQ:KERX

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

MannKind stock logo

MannKind NASDAQ:MNKD

$4.20 +0.08 (+1.94%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.23 +0.03 (+0.71%)
As of 05/27/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.